Market and company headlines
Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and raises the price target from $145 to $180.
Benzinga·05:13·8 Days AgoRGEN
Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. See why RGEN stock is a Buy.
SeekingAlpha·19:57RGEN
Webcast and Conference Call to Be Held Tuesday, October 27, 2026, at 8:00 a.m. ETWALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended September 30,
Yahoo·07:30RGEN
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.
Benzinga·07:20RGEN
